Revolutionizing Air Compressor Operation: ELGi Unveils Ground-breaking “STABILISOR” Technology
Setting New Standards in Compressed Air Reliability, Energy Costs, and Variable Flow
In a significant leap forward for industrial air compression, Elgi Equipments (BSE: 522074; NSE: ELGIEQUIP), one of the world's leading air-compressor manufacturers with over 64 years of compressed air excellence, today announced the introduction of its pioneering compressed air stabilization technology. Designed to revolutionize the way compressors operate in plants with dynamic air demand, the STABILISOR system aims to address the longstanding challenges of unstable compressor performance, inefficiency, and excessive wear caused by frequent load/unload cycles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250204651563/en/
Patented Compressed Air Stabilization Technology (Graphic: Elgi Equipments)
In industrial settings, the gap between compressor capacity and plant air demand is inherently dynamic. This variability leads to frequent cut-in and cut-out operations, which destabilize the compressor and impair critical flow and kinematic components. Traditional solutions, such as increasing reservoir volume, altering cut-in/cut-out pressures, or adding variable frequency drives (VFDs), often fall short, introducing new inefficiencies or higher operational costs.
“The STABILISOR system employs a first of its kind 'Recirculate and Recover' principle, seamlessly aligning compressor capacity with plant air demand through controlled recirculation and recovery techniques. By stabilizing airflows within the system, the STABILISOR system minimizes load/unload cycles, ensuring extended equipment lifespan, optimizes energy use, achieving up to 15% energy savings in typical applications, while reducing system inefficiencies, maintaining superior performance across varying demand patterns. With its energy-efficient design and potential to reduce wear-and-tear, the STABILISOR aligns with global sustainability goals. Its implementation in industrial plants represents a shift towards greener, more cost-effective manufacturing processes,” said Dr. Jairam Varadaraj, Managing Director, Elgi Equipments Ltd.
Dr. Venu Madhav, Director, Technology, Elgi Equipments Ltd said “The STABILISOR system utilizes precision-engineered progressive and on-off valves to recirculate excess capacity within the system. This system leverages stabilization zones and low-pressure recovery techniques to - balance airflow demands dynamically, minimize energy losses by targeting pressure points with minimal differences all while maximizing overall system reliability.”
To meet diverse operational needs, the STABILISOR system, will be available in India and across the globe, in 2025, in two versions:
- Light Version: Designed for field fitment, energy savings and enhanced reliability.
- Heavy Version: Factory-fitted for superior energy savings and comprehensive stability.
The STABILISOR’s innovative design and control methodology has been patented worldwide, marking it as a pioneering advancement in compressed air technology. To learn more about ELGi's advanced compressed air solutions, visit www.elgi.com.
About ELGi: Elgi Equipments Limited is a global air compressor manufacturer renowned for its extensive range of innovative and technologically advanced compressed air systems. Committed to maximizing customer productivity and minimizing ownership costs, ELGi offers customers a comprehensive range of compressed air solutions designed to enhance energy efficiency and power superior performance. To learn more, please visit http://www.elgi.com.
--------------------------------------------------------------------------------------
FOLLOW US AT OUR GLOBAL PLATFORMS FOR ALL THE DEVELOPMENTS AND NEWS
Facebook | Twitter | LinkedIn | YouTube | Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204651563/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom